Kim Sonya, Mortera Marianne, Heyn Patricia C, Sood Pallavi, Wen Pey-Shan, Chen Wong Diana, Tanveer Sarah, Hu Xiaolei
Department of Neurology and Department of Rehabilitation Medicine, New York University Grossman School of Medicine, New York, USA.
NYU Steinhardt, Department of Occupational Therapy, New York University, New York, USA.
Brain Inj. 2022 Jun 7;36(7):829-840. doi: 10.1080/02699052.2022.2087102. Epub 2022 Jun 16.
There is a need for an overview of systematic reviews (SRs) examining randomized clinical trials (RCTs) of pharmacological interventions in the treatment of intracranial pressure (ICP) post-TBI.
To summarize pharmacological effectiveness in decreasing ICP in SRs with RCTs and evaluate study quality.
Comprehensive literature searches were conducted in MEDLINE, PubMed, EMBASE, PsycINFO, and Cochrane Library databases for English SRs through October 2020. Inclusion criteria were SRs with RCTs that examined pharmacological interventions to treat ICP in patients post-TBI. Data extracted were participant characteristics, pharmacological interventions, and ICP outcomes. Study quality was assessed with AMSTAR-2.
Eleven SRs between 2003 and 2020 were included. AMSTAR-2 ratings revealed 3/11 SRs of high quality. Pharmacological interventions included hyperosmolars, neuroprotectives, anesthetics, sedatives, and analgesics. Study samples ranged from 7 to 1282 patients. Hyperosmolar agents and sedatives were beneficial in lowering elevated ICP. High bolus dose opioids had a more deleterious effect on ICP. Neuroprotective agents did not show any effects in ICP management.
RCT sample sizes and findings in the SRs varied. A lack of detailed data syntheses was noted. AMSTAR-2 analysis revealed moderate to high quality in most SRs. Future SRs may focus on streamlined reporting of dosing and clearer clinical recommendations. PROSPERO-Registration: CRD42015017355.
需要对系统评价(SRs)进行综述,这些系统评价考察了药物干预治疗创伤性脑损伤(TBI)后颅内压(ICP)的随机临床试验(RCTs)。
总结随机对照试验的系统评价中降低颅内压的药物有效性,并评估研究质量。
截至2020年10月,在MEDLINE、PubMed、EMBASE、PsycINFO和Cochrane图书馆数据库中进行全面的文献检索,以查找英文系统评价。纳入标准为包含考察治疗TBI后患者颅内压的药物干预的随机对照试验的系统评价。提取的数据包括参与者特征、药物干预和颅内压结果。使用AMSTAR-2评估研究质量。
纳入了2003年至2020年间的11项系统评价。AMSTAR-2评分显示11项系统评价中有3项高质量。药物干预包括高渗剂、神经保护剂、麻醉剂、镇静剂和镇痛药。研究样本量从7例到1282例患者不等。高渗剂和镇静剂有助于降低升高的颅内压。高剂量推注阿片类药物对颅内压有更有害的影响。神经保护剂在颅内压管理中未显示任何效果。
系统评价中的随机对照试验样本量和结果各不相同。注意到缺乏详细的数据综合分析。AMSTAR-2分析显示大多数系统评价质量为中等至高。未来的系统评价可能侧重于简化剂量报告和更明确的临床建议。PROSPERO注册编号:CRD42015017355。